Search
+
    SEARCHED FOR:

    VULGARIS

    Glenmark, Cosmo get MHRA nod for acne treatment medication

    Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval to market Winlevi, a topical acne treatment for patients aged 12 and older in the UK. Glenmark licensed the product from Cosmo for distribution in Europe and South Africa, aiming to improve the quality of life for those suffering from acne, which affects a significant portion of the global population.

    Your nose may be warning you about serious health issues: Vital nasal signals you shouldn't miss

    The nose provides valuable health cues. Persistent congestion, unusual smells, or changes in appearance could signal health issues. Acne vulgaris and rosacea can affect the nose. Sarcoidosis may cause bluish rashes, and trigeminal trophic syndrome can numb the nose. Monitoring these signs can aid early diagnosis and treatment of underlying conditions.

    Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan

    Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.

    Why is retinol considered the antidote to ageing?

    Retinol is a catch-all term often used to describe vitamin A and other retinoids (a group of fat-soluble compounds consisting of retinol and other structurally related substances).

    Love pulses? Here's five interesting trivia about this superfood

    According to researchers, pulses may be the key to curing world hunger.

    Dr Reddy's completes clinical studies of its proposed rituximab biosimilar candidate

    Following completion of the full set of clinical studies, Dr Reddy's said it will now prepare to file in the US, European Union and other regions for approval of 'DRL_RI'.

    The Economic Times
    BACK TO TOP